Synthesis, characterization and biological activity of novel CU(II), PD(II), PT(II) complexes with 2-hydroxy-8-ethyltricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone

Pakhontsu E.; Paraschivescu Codruța; Ilies D.; Poirier Donald; Oprean Camelia; Gulya Aurelian; Roshu T.

Articolul precedent

Articolul urmator

648

Ultima descărcare din IBN:
2022-12-08 09:04

SM ISO690:2012

PAKHONTSU, E., PARASCHIVESCU, Codruța, ILIES, D., POIRIER, Donald, OPREAN, Camelia, GULYA, Aurelian, ROSHU, T.. Synthesis, characterization and biological activity of novel CU(II), PD(II), PT(II) complexes with 2-hydroxy-8-ethyltricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone. In: Physical Methods in Coordination and Supramolecular Chemistry, 8-9 octombrie 2015, Chişinău. Chisinau, Republic of Moldova: 2015, XVIII, p. 114.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Physical Methods in Coordination and Supramolecular Chemistry
XVIII, 2015

Conferința ""Physical Methods in Coordination and Supramolecular Chemistry""
Chişinău, Moldova, 8-9 octombrie 2015

Synthesis, characterization and biological activity of novel CU(II), PD(II), PT(II) complexes with 2-hydroxy-8-ethyltricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone

Pag. 114-114

Pakhontsu E.¹, Paraschivescu Codruța², Ilies D.², Poirier Donald³, Oprean Camelia⁴, Gulya Aurelian⁵, Roshu T.²

¹ University of Medicine and Pharmacy “Carol Davilla”, Bucharest,
² University of Bucharest,
³ CHU de Quebec – Research Center (CHUL, T4),
⁴ Victor Babes University of Medicine and Pharmacy, Timişoara,
⁵ Moldova State University

Disponibil în IBN: 22 aprilie 2020

Descarcă PDF

Rezumat

The chemistry of transition metal complexes of thiosemicarbazones have gained considerable attention due to their diverse applications in the pharmacological field as antimicrobial agents [1- 4] and found to have in vitro cytotoxic effects against cancer cells [5]. In this research, we have synthesized and characterized new Cu(II), Pd(II) and Pt(II) complexes: [Cu(L)(H2O)2(OAc)](1),[Cu(L)(H2O)2(SO4)](2),[Cu(L)(H2O)2(NO3)](3),[Cu(L)(H2O)2(ClO4)](4), [Cu(L)2(H2O)2] (5), [Pd(L)(OAc)]H2O (6), [Pt(L)2] (7) were HL= 2-hydroxy-8-ethyl-tricyclo [7.3.1.0.2,7]tridecane-13-one-thiosemicarbazone. The ligand has been characterized by elemental analyses, IR, 1H NMR and 13C NMR spectroscopy, mass spectroscopy. All complexes have been characterized by IR, 1H NMR, 13C NMR, UV-Vis, FAB, EPR, mass spectroscopy, elemental and thermal analysis, magnetic susceptibility measurements and molar electric conductivity. The physico-chemical analyses confirmed the composition and the structure of the newly obtained complex combinations. All complexes with 2-hydroxy-8-R-tricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone have been tested for their antimicrobial activity against Escherichia coli, Salmonella enteritidis, Staphylococcus aureus, Enterococcus, Candida albicans and cytotoxicity against SKBR-3 human breast, MCF-7 human breast, A375 human melanoma cancer cells and HL-60 human promyelocytic leukemia cells.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-101866</cfResPublId>
<cfResPublDate>2015</cfResPublDate>
<cfVol>XVIII</cfVol>
<cfStartPage>114</cfStartPage>
<cfISBN></cfISBN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/101866</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Synthesis, characterization and biological activity of novel CU(II), PD(II), PT(II) complexes with 2-hydroxy-8-ethyltricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone</cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The chemistry of transition metal complexes of thiosemicarbazones have gained considerable attention due to their diverse applications in the pharmacological field as antimicrobial agents [1- 4] and found to have in vitro cytotoxic effects against cancer cells [5]. In this research, we have synthesized and characterized new Cu(II), Pd(II) and Pt(II) complexes: [Cu(L)(H2O)2(OAc)](1),[Cu(L)(H2O)2(SO4)](2),[Cu(L)(H2O)2(NO3)](3),[Cu(L)(H2O)2(ClO4)](4), [Cu(L)2(H2O)2] (5), [Pd(L)(OAc)]H2O (6), [Pt(L)2] (7) were HL= 2-hydroxy-8-ethyl-tricyclo [7.3.1.0.2,7]tridecane-13-one-thiosemicarbazone. The ligand has been characterized by elemental analyses, IR, 1H NMR and 13C NMR spectroscopy, mass spectroscopy. All complexes have been characterized by IR, 1H NMR, 13C NMR, UV-Vis, FAB, EPR, mass spectroscopy, elemental and thermal analysis, magnetic susceptibility measurements and molar electric conductivity. The physico-chemical analyses confirmed the composition and the structure of the newly obtained complex combinations. All complexes with 2-hydroxy-8-R-tricyclo[7.3.1.0.2,7]tridecane-13-one thiosemicarbazone have been tested for their antimicrobial activity against Escherichia coli, Salmonella enteritidis, Staphylococcus aureus, Enterococcus, Candida albicans and cytotoxicity against SKBR-3 human breast, MCF-7 human breast, A375 human melanoma cancer cells and HL-60 human promyelocytic leukemia cells.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-21973</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-75604</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-61248</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-15307</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-40437</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-499</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-21190</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-21973</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21973-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Pakhontsu</cfFamilyNames>
<cfFirstNames>E.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-75604</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-75604-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Paraschivescu</cfFamilyNames>
<cfFirstNames>Codruța</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-61248</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-61248-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Ilies</cfFamilyNames>
<cfFirstNames>D.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-15307</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-15307-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Poirier</cfFamilyNames>
<cfFirstNames>Donald</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-40437</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-40437-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Oprean</cfFamilyNames>
<cfFirstNames>Camelia</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-499</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-499-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Gulya</cfFamilyNames>
<cfFirstNames>Aurelian</cfFirstNames>
<cfFamilyNames>Гуля</cfFamilyNames>
<cfFirstNames>Аурелиан</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-21190</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21190-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2015T24:00:00</cfStartDate>
<cfFamilyNames>Roshu</cfFamilyNames>
<cfFirstNames>T.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>